Those who’ve dodged COVID-19 for more than four years may have a newly discovered immune response to thank. The results stem from a challenge trial: At the height of the pandemic in 2021, scientists ...
We conducted a phase 2–3 double-blind trial to assess the efficacy and safety of nirmatrelvir–ritonavir in asymptomatic, rapid antigen test–negative adults who had been exposed to a household contact ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results